TRACON PHARMACEUTICALS INC's ticker is TCON and the CUSIP is 89237H209.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24 | -42.9% | 134,538 | -6.2% | 0.00% | – |
| Q2 2023 | $42 | -86.8% | 143,484 | -14.9% | 0.00% | – |
| Q1 2023 | $319 | +58.7% | 168,600 | +24.8% | 0.00% | – |
| Q4 2022 | $201 | -99.8% | 135,049 | +98.9% | 0.00% | – |
| Q3 2022 | $113,000 | +7.6% | 67,900 | +29.1% | 0.00% | – |
| Q2 2022 | $105,000 | +36.4% | 52,600 | +80.1% | 0.00% | – |
| Q1 2022 | $77,000 | -86.8% | 29,200 | -86.2% | 0.00% | -100.0% |
| Q4 2021 | $584,000 | -50.8% | 211,000 | -31.3% | 0.00% | -50.0% |
| Q3 2021 | $1,188,000 | +5.5% | 306,976 | +76.9% | 0.00% | +100.0% |
| Q2 2021 | $1,126,000 | -43.1% | 173,535 | -27.9% | 0.00% | -50.0% |
| Q1 2021 | $1,980,000 | +0.1% | 240,600 | +42.3% | 0.00% | 0.0% |
| Q4 2020 | $1,978,000 | +369.8% | 169,100 | +107.5% | 0.00% | – |
| Q3 2020 | $421,000 | -22.6% | 81,500 | -70.6% | 0.00% | – |
| Q2 2020 | $544,000 | +38.1% | 277,396 | +19.7% | 0.00% | – |
| Q1 2020 | $394,000 | +11.0% | 231,729 | +52.9% | 0.00% | – |
| Q4 2019 | $355,000 | – | 151,529 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 4,125,322 | $8,251,000 | 3.72% |
| Ikarian Capital, LLC | 2,788,853 | $5,577,000 | 1.02% |
| Telemetry Investments, L.L.C. | 100,000 | $200,000 | 0.24% |
| ACT CAPITAL MANAGEMENT, LLC | 28,500 | $57,000 | 0.08% |
| JOHNSON & JOHNSON | 84,003 | $168,000 | 0.04% |
| NEA Management Company, LLC | 346,719 | $693,000 | 0.04% |
| X-Square Capital, LLC | 17,973 | $36,000 | 0.02% |
| BOOTHBAY FUND MANAGEMENT, LLC | 268,301 | $537,000 | 0.01% |
| LINDEN ADVISORS LP | 454,916 | $910,000 | 0.01% |
| DOWLING & YAHNKE LLC | 47,455 | $95,000 | 0.00% |